Stifel reiterates Alkermes stock rating on pipeline confidence

Investing.com reports that Stifel has reaffirmed its Buy rating and set a $63 price target for Alkermes (NASDAQ:ALKS) shares, following discussions with the company's executives. The price target indicates a potential 51% increase from the stock's current value of $41.75, which has already risen 49% year-to-date. During a non-deal roadshow on the West Coast, Stifel CEO Blair Jackson and investor relations representative Sandy Coombs met with Alkermes officials.

The firm's confidence stems from the anticipated results of Vibrance-3 phase 2 trials for idiopathic hypersomnia and the strong enrollment in Brilliance phase 3 trials for narcolepsy type 1 and type 2. Topline data from these trials could be released as early as next summer. Stifel's assessment, supported by AI, places the stock near its Fair Value and reports a "Good" financial health score.

Investors can access additional exclusive insights through InvestingPro. Alkermes has also recently showcased promising results from its Phase Ib trial for an ADHD drug candidate, ALKS 7290, which demonstrated safety and efficacy in reducing ADHD symptoms. This development, along with other positive news, has prompted TD Cowen to upgrade its rating to Buy with a $58.00 price target, while Mizuho maintained an Outperform rating with a $65.00 target.

Analyst opinions on Alkermes vary, with Goldman Sachs offering a Neutral rating and a $50.00 price target. These ratings and targets highlight the differing levels of confidence analysts have in the company's future performance, making it essential for investors to consider this information when evaluating the stock.